Mark Baldry
Known title: Chief Commercial OfficerCIK: 0001644137
Mark Baldry's purchase track record
How the stock did after each of Mark Baldry's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since May 17, 2024
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-56.5%
3 months: -2.4%
Beat the S&P 500
33%
median -67.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2025 | XFOR | $3K | -2.4% | +25.3% | +13.0% |
| 11/15/2024 | XFOR | $5K | +25.7% | -75.9% | +1.5% |
| 5/17/2024 | XFOR | $15K | -25.1% | -56.5% | +10.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XFOR | ▲ Buy | Open Market | 1,032 | $3K | 5/16/2025 | View on chart |
| XFOR | ▲ Buy | Grant | 600,000 | $0 | 2/12/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 29,159 | $13K | 1/24/2025 | View on chart |
| XFOR | ▲ Buy | Grant | 74,773 | $0 | 1/23/2025 | View on chart |
| XFOR | ▲ Buy | Open Market | 13,404 | $5K | 11/15/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 11,127 | $7K | 10/7/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 34,946 | $0 | 10/4/2024 | View on chart |
| XFOR | ▲ Buy | Open Market | 21,646 | $15K | 5/17/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 10,257 | $7K | 11/1/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 34,947 | $0 | 10/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.